A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Samuelsson C) > (2010-2014) > A phase II study of...

LIBRIS Formathandbok (Information om MARC21)

Details
MARC

Fältnamn	Indikatorer	Metadata
000		04993naa a2200649 4500
001		oai:DiVA.org:uu-206429
003		SwePub
008		130830s2013 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:DiVA.org:oru-56398
009		oai:prod.swepub.kib.ki.se:127078674
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2064292 URI
024	7	a https://doi.org/10.1111/bjh.124162 DOI
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-563982 URI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:1270786742 URI
040		a (SwePub)uud (SwePub)orud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Andersen, Christen L.u Dept Haematol, Roskilde Hosp, Roskilde, Denmark.; Dept Haematol, Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark4 aut
245	1 0	a A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
264		c 2013-06-11
264	1	b Wiley,c 2013
338		a print2 rdacarrier
520		a Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat was followed by a decline in clonal myeloproliferation as defined by European Leukaemia Net. Thirty patients (48%) completed the intervention period (24 weeks of therapy). An intention-to-treat response rate of 35% was identified. Pruritus was resolved [19% to 0% (P=0.06)] and the prevalence of splenomegaly was lowered from 50% to 27% (P=0.03). Sixty-five per cent of the patients experienced a decrease in JAK2 V617F allele burden (P=0.006). Thirty-three patients (52% of patients) discontinued study drug before end of intervention due to adverse events (28 patients) or lack of response (5 patients). In conclusion, vorinostat showed effectiveness by normalizing elevated leucocyte and platelet counts, resolving pruritus and significantly reducing splenomegaly. However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653		a essential thrombocythaemia
653		a polycythaemia vera
653		a phase II study
653		a histone deacetylase inhibition
653		a vorinostat
700	1	a McMullin, Mary F.u Dept Haematol, Queens Univ Belfast, Antrim, North Ireland4 aut
700	1	a Ejerblad, Elisabethu Uppsala universitet,Hematologi,Dept Haematol, Univ Uppsala Hosp, Uppsala, Sweden4 aut0 (Swepub:uu)eleje020
700	1	a Zweegman, Sonjau Dept Haematol, Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands4 aut
700	1	a Harrison, Claireu Dept Haematol, Guys & St Thomas Hosp, London, England; NHS Foundation Trust, London, England4 aut
700	1	a Fernandes, Savio4 aut
700	1	a Bareford, Davidu Dept Haematol, Russells Hall Hosp, Dudley, England4 aut
700	1	a Knapper, Stevenu Dept Haematol, Cardiff Univ, Cardiff, S Glam, UK4 aut
700	1	a Samuelsson, Janu Karolinska Institutet4 aut
700	1	a Loefvenberg, Evau Haematol Ctr, Karolinska Univ Hosp, Stockholm, Sweden4 aut
700	1	a Linder, Olle4 aut
700	1	a Andreasson, Bjornu Dept Haematol, NU Hosp Org, Uddevalla Hosp, Uddevalla, Sweden4 aut
700	1	a Ahlstrand, Eriku Region Örebro län4 aut0 (Swepub:oru)ead
700	1	a Jensen, Morten K.u Dept Haematol, Herlev Hosp, Herlev, Denmark4 aut
700	1	a Bjerrum, Ole W.4 aut
700	1	a Vestergaard, Hanneu Dept Haematol, Odense Univ Hosp, Odense, Denmark4 aut
700	1	a Larsen, Herdisu Dept Internal Med, Dept Haematol, Viborg Hosp, Viborg, Denmark4 aut
700	1	a Klausen, Tobias W.4 aut
700	1	a Mourits-Andersen, Torbenu Dept Haematol, Esbjerg Cent Hosp, Esbjerg, Denmark4 aut
700	1	a Hasselbalch, Hans C.u Dept Haematol, Roskilde Hosp, Roskilde, Denmark4 aut
710	2	a Dept Haematol, Roskilde Hosp, Roskilde, Denmark.; Dept Haematol, Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmarkb Dept Haematol, Queens Univ Belfast, Antrim, North Ireland4 org
773	0	t British Journal of Haematologyd : Wileyg 162:4, s. 498-508q 162:4<498-508x 0007-1048x 1365-2141
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-206429
856	4 8	u https://doi.org/10.1111/bjh.12416
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-56398
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:127078674

Find in a library

British Journal of Haematology (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Hematology

Articles in the publication: British Journal ...

By the university: Uppsala University; Örebro University; Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se